Jazz Pharmaceuticals (JAZZ) Other Non-Current Liabilities (2012 - 2026)

Jazz Pharmaceuticals' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $161.5 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 77.24% year-over-year to $161.5 million; the TTM figure through Mar 2026 stood at $161.5 million (up 77.24% YoY), while the FY2025 annual figure was $124.4 million, up 43.63% from the prior year.
• Other Non-Current Liabilities was $161.5 million for Q1 2026 at Jazz Pharmaceuticals, up from $124.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $161.5 million in Q1 2026 to a low of $86.6 million in Q4 2024.
• Historically, Other Non-Current Liabilities has averaged $116.6 million across 5 years, with a median of $122.7 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities slipped 29.41% in 2024, then soared 77.24% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $144.0 million in 2022, then declined by 14.78% to $122.7 million in 2023, then decreased by 29.41% to $86.6 million in 2024, then soared by 43.63% to $124.4 million in 2025, then increased by 29.82% to $161.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $161.5 million (Q1 2026), $124.4 million (Q4 2025), and $108.9 million (Q3 2025), per Business Quant data.